Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982394priorityCriticalpatent/ECSP982394A/en
Publication of ECSP982394ApublicationCriticalpatent/ECSP982394A/en
La presente invención se refiere a derivados de ácidos arilsulfonilaminohidroxámicos que son inhibidores de metaloproteinasa matriciales o de la producción de factor de mecrosis tumoral (TNF) y, como tales, son útiles en el tratamiento de una condición seleccionada del grupo formado por artritis, cáncer, ulceración de tejidos, estenosis, enfermedad periodontal, epidermolises ampollosa, escleritis y otras enfermedades caracterizadas por actividad metaloproteinasas matriciales, SIDA, sepsis, shock séptico y otras enfermedades que implican la producción de TNF. Además, los compuestos de la presente invención se puede usar en terapia combinada con fármacos antiinflamatorios no esteroideos.The present invention relates to arylsulfonylaminohydroxamic acid derivatives that are inhibitors of matrix metalloproteinase or tumor mecrosis factor (TNF) production and, as such, are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, stenosis, periodontal disease, epidermolyses bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock, and other diseases involving TNF production. Furthermore, the compounds of the present invention can be used in combination therapy with non-steroidal anti-inflammatory drugs.
COMPOUNDS THAT FIX THE G-QUADRUPLEX STRUCTURE OF TELOMERES, TRIAZINS FOR THE APPLICATION OF SUCH COMPOUNDS, THE USE OF SUCH COMPOUNDS AS PHARMACEUTICAL PRODUCTS AND INCLUDING THERAPEUTICAL ASSOCIATIONS.